Search
01/01/2022
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial
Moreno C., Greil R., Demirkan F., Tedeschi A., Anz B., Larratt L., Simkovic M., Novak J., Strugov V., Gill D., Gribben J.G., Kwei K., Dai S., Hsu E., Dean J.P., Flinn I.W.. First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial. HAEMATOLOGICA. 2022; 107(9)DOI:10.3324/haematol.2021.279012. PMID:35021599. IF:10.100(Q1/2D).
01/01/2022
Correction: The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years (Leukemia, (2022), 36, 6, (1646-1653), 10.1038/s41375-022-01563-8)
Bazarbachi A., Boumendil A., Finel H., Khvedelidze I., Romejko-Jarosinska J., Tanase A., Akhtar S., Ben Othman T., Ma’koseh M., Afanasyev B., El-Cheikh J., Briones J., Gülbas Z., Hamladji R.-M., Elverdi T., Blaise D., Martínez C., Alma E., Halaburda K., Sousa A.B., Glass B., Robinson S., Montoto S., Sureda A.. Correction: The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years (Leukemia, (2022), 36, 6, (1646-1653), 10.1038/s41375-022-01563-8). LEUKEMIA. 2022; 36(8)DOI:10.1038/s41375-022-01639-5. PMID:35840758. IF:11.400(Q1/1D).
01/01/2022
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia
Barr P.M., Owen C., Robak T., Tedeschi A., Bairey O., Burger J.A., Hillmen P., Coutre S.E., Dearden C., Grosicki S., McCarthy H., Li J.-Y., Offner F., Moreno C., Zhou C., Hsu E., Szoke A., Kipps T.J., Ghia P.. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Advances. 2022; 6(11)DOI:10.1182/bloodadvances.2021006434. PMID:35377947. IF:7.500(Q1/2D).
01/01/2022
Medicina de precisión en leucemia linfática crónica: Análisis de coste-efectividad de nuevas combinaciones dirigidas
Meijide J.B.. Medicina de precisión en leucemia linfática crónica: Análisis de coste-efectividad de nuevas combinaciones dirigidas. Farmacia Hospitalaria. 2022; 46(3)DOI:10.7399/fh.13280. PMID:36183201. IF:(Q/D).
01/12/2025
Reticulocyte Count Interference at the Onset of Acute Myeloid Leukemia
Gutiérrez-Hernández, MD, Ramil, G, González-Alvarez, N, San-José, P. Reticulocyte Count Interference at the Onset of Acute Myeloid Leukemia. International Journal of Laboratory Hematology. 2025; 47(6)DOI:10.1111/ijlh.14545. PMID:40836604. IF:2.300(Q2/5D).
01/12/2025
Patient selection and treatment outcomes over time in patients with large B-cell lymphoma receiving car T-cell therapy
Torrent, A, Morgades, M, Iacoboni, G, Reguera, JL, Kwon, M, Corral, LL, Hernani, R, Ortiz-Maldonado, V, Sanz, J, Gonzalez, ACC, Guerra, L, Pina, JMS, Mussetti, A, Garcia-Sancho, AM, Bastos-Oreiro, M, Delgado, J, Carpio, C, Sancho, JM, Perez-Martinez, A, Barba, P. Patient selection and treatment outcomes over time in patients with large B-cell lymphoma receiving car T-cell therapy. BONE MARROW TRANSPLANTATION. 2025; 60(12)DOI:10.1038/s41409-025-02722-y. PMID:41028300. IF:5.200(Q1/1D).